Literature DB >> 30005854

Drug-induced lupus: Traditional and new concepts.

Augusto Vaglio1, Peter C Grayson2, Paride Fenaroli3, Davide Gianfreda3, Valeria Boccaletti4, Gian Marco Ghiggeri5, Gabriella Moroni6.   

Abstract

Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-nuclear antibodies; Autoimmunity; Lupus; NETosis; TNF inhibitors

Mesh:

Year:  2018        PMID: 30005854     DOI: 10.1016/j.autrev.2018.03.016

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  15 in total

1.  Drug-Induced Lupus, a One-time Hit or a Harbinger of Future Autoimmunity: A Case Report.

Authors:  David Kirakossian; Pradipta Ghosh
Journal:  Perm J       Date:  2020-03-13

2.  A simultaneous presentation of drug-induced lupus with drug-induced ANCA vasculitis secondary to hydralazine use in a patient with sarcoidosis.

Authors:  Maria Catalina Espinosa; Belicia Ding; Kati Choi; Daniel N Cohen; Marco Marcelli; Onome Whiteru Ifoeze
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-27

Review 3.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27

Review 4.  New insights into the role of antinuclear antibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2020-09-03       Impact factor: 20.543

5.  Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature.

Authors:  Iacopo Gianassi; Marco Allinovi; Leonardo Caroti; Lino Calogero Cirami
Journal:  World J Nephrol       Date:  2019-11-12

6.  Severe lupus induced by the tumor necrosis factor-alpha inhibitor Anbainuo: a case report.

Authors:  Xiaoli Pan; Yuan Yuan; Fei Huang; Mei Tian
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

7.  Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Faslpr Mice.

Authors:  Akiko Nagasu; Tomoyuki Mukai; Masanori Iseki; Kyoko Kawahara; Shoko Tsuji; Hajime Nagasu; Yasuyoshi Ueki; Katsuhiko Ishihara; Naoki Kashihara; Yoshitaka Morita
Journal:  Cells       Date:  2019-04-30       Impact factor: 6.600

8.  Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.

Authors:  Cristina Solé; Elsa Solà; Patricia Huelin; Marta Carol; Rebeca Moreira; Unai Cereijo; José-Manuel Mas; Isabel Graupera; Elisa Pose; Laura Napoleone; Gloria dePrada; Adrià Juanola; Núria Fabrellas; Ferran Torres; Manuel Morales-Ruiz; Judith Farrés; Wladimiro Jiménez; Pere Ginès
Journal:  Liver Int       Date:  2019-02-17       Impact factor: 5.828

Review 9.  Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.

Authors:  Alicia J Little; Matthew D Vesely
Journal:  Yale J Biol Med       Date:  2020-03-27

Review 10.  The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases.

Authors:  José M Carballido; Camille Regairaz; Celine Rauld; Layla Raad; Damien Picard; Michael Kammüller
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.